Circulating Tumor Cells and the CellSearch Assay

Overall Survival in MBC

April 2011

Kaplan-Meier analyses were also performed to determine whether circulating tumor cell counts could predict overall survival. The graph on the left shows that when comparing the favorable and unfavorable groups, the median overall survival was shown to be significantly longer in the favorable group than in the unfavorable group (21.9 versus 10.9 months).

The graph on the right shows that metastatic breast cancer patients who had =5 CTCs at all timepoints after the initiation of therapy had a much shorter overall survival of 4.1 months. Whereas those patients that were less than 5 CTCs at all time points had the longest overall survival of 22.6 months. Interestingly, those patients who have = 5 CTCs at baseline but eventually decreased to less than 5 CTCs after the start of therapy have approximately the same risk of death as those who never exceed the 5 circulating tumor cells threshold.

This led to the FDA approval of the CellSearch system for use in metastatic breast cancer patients in 2004.

< Previous Slide

Overall Survival in MBC

Next Slide >

 

Jump to section:

• Introduction
• Circulating Tumor Cell (CTC)
• The Metastatic Process
• Needle in a Haystack...
• Circulating Tumor Cells
• The CellSearch System (Veridex LLC)
• Automated Sample Preparation
• Labeling and Identification of CTCs
• Labeling and Identification of Cells
• Cell Analysis
• Mayo Medical Laboratories FDA-Cleared Assays
• Metastatic Breast Cancer (MBC)
• CellSearch Use in MBC Clinical Trial⁶
• Progression-Free Survival in MBC
• Overall Survival in MBC
• Metastatic Colorectal Cancer (MCRC)
• CellSearch Use in MCRC Clinical Trial⁸
• Progression-Free Survival in MCRC
• Overall Survival in MCRC
• Metastatic Prostate Cancer (MPC)
• CellSearch Use in MPC Clinical Trial⁸
• Progression-Free Survival in MPC
• Overall Survival in MPC
• The Future of CTC
• References
• Questions?